FN1 and parasitic infectious disease: The TGF-β receptor inhibitor GW788388 led to a reduction in parasitemia, mortality and prevented the development of fibrosis with a significant reduction in fibronectin and collagen I when administered to mice infected with T. cruzi in the acute phase [73].